Iambic Therapeutics just found out what public investors think of an AI-powered cancer drug developer. The answer, at least on day one, was enthusiastic.
The San Diego biotech’s shares rose 16% to $18.50 in their Nasdaq debut on October 15, 2026. The move came after a $150 million initial public offering, and it lands at a moment when AI in drug discovery is one of the most closely watched bets in biotech.
How the offering came together
Iambic priced its IPO on October 14, 2026, at $16 per share. That figure sat right at the midpoint of its projected range.
The company sold 9.375 million shares to raise the $150 million. The stock now trades under the ticker IAM.
The opening wasn’t entirely smooth. Shares hit a volatility halt before settling into their gain.
Based on its outstanding shares, the debut put Iambic’s market value somewhere between approximately $758 million and $877 million.
The IPO also adds to a hefty private war chest. Iambic had raised more than $460 million in private funding since it was founded.
What Iambic actually does
The company uses proprietary AI systems called NeuralPLexer and Enchant. It pairs them with automated, high-throughput chemistry and biology labs that test candidates at scale.
Iambic’s stated ambition is to move candidates from design into clinical trials in approximately two years. It focuses on small-molecule drugs with oncology as its main battleground.
Its lead candidate is IAM1363, a HER2 inhibitor designed to penetrate the brain. IAM1363 is currently in Phase 1/1b trials for HER2-altered solid tumors. Iambic anticipates that a registrational study could begin as early as 2027.
Behind that lead program sit preclinical candidates aimed at KIF18A and CDK2/4.
A cap table with name recognition
Iambic’s backer list includes Nvidia, ARK Investment Management, and Sequoia.
The company was founded in 2019 under the name Entos and rebranded in 2023. It now employs approximately 171 people.
The financials investors are weighing
In figures through June 30, 2026, the company reported a net loss of $94.25 million.
It did book $18.25 million in collaboration revenue over that period.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.